Jacob Chacko - Feb 1, 2022 Form 4 Insider Report for Oric Pharmaceuticals, Inc. (ORIC)

Role
President and CEO, Director
Signature
/s/ Christian Kuhlen, attorney-in-fact
Stock symbol
ORIC
Transactions as of
Feb 1, 2022
Transactions value $
$0
Form type
4
Date filed
2/2/2022, 03:04 PM
Previous filing
Sep 16, 2021
Next filing
Mar 25, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ORIC Stock Option (right to buy) Award $0 +300K $0.00 300K Feb 1, 2022 Common Stock 300K $9.48 Direct F1
transaction ORIC Restricted Stock Unit Award $0 +50K $0.00 50K Feb 1, 2022 Common Stock 50K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option shall vest on February 1, 2023, and 1/36th of the remaining shares subject to the option shall vest each month thereafter.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock.
F3 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024.